MCID: DRG003
MIFTS: 48

Drug Dependence

Categories: Mental diseases

Aliases & Classifications for Drug Dependence

MalaCards integrated aliases for Drug Dependence:

Name: Drug Dependence 12 55 15 17 72

Classifications:



External Ids:

Disease Ontology 12 DOID:9974
ICD9CM 35 304.6 304.60
UMLS 72 C0029792 C1510472

Summaries for Drug Dependence

Disease Ontology : 12 A substance dependence that involves the continued use of drugs despite problems related to use of the substance.

MalaCards based summary : Drug Dependence is related to polysubstance abuse and hallucinogen dependence. An important gene associated with Drug Dependence is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Aripiprazole and Ketamine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Drug Dependence

Diseases related to Drug Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 197)
# Related Disease Score Top Affiliating Genes
1 polysubstance abuse 32.7 DRD3 DRD2 CNR1
2 hallucinogen dependence 31.7 PENK CNR1
3 substance abuse 31.2 SLC6A4 DRD3 DRD2
4 opiate dependence 31.0 SLC6A4 POMC PDYN OPRM1 OPRK1 OPRD1
5 personality disorder 30.9 SLC6A4 DRD2 ANKK1
6 substance dependence 30.7 SLC6A4 POMC OPRM1 OPRK1 OPRD1 DRD3
7 antisocial personality disorder 30.7 SLC6A4 DRD2 ANKK1
8 morphine dependence 30.6 OPRM1 OPRK1 OPRD1
9 neonatal abstinence syndrome 30.6 OPRM1 OPRK1 OPRD1
10 mental depression 30.3 SLC6A4 POMC CRH
11 panic disorder 30.1 SLC6A4 POMC CRH
12 cocaine dependence 30.1 SLC6A4 POMC PDYN OPRM1 OPRK1 OPRD1
13 opioid addiction 30.0 PNOC OPRM1 OPRK1 OPRD1 DRD2
14 opioid abuse 30.0 PDYN OPRM1 OPRL1 DRD2
15 withdrawal disorder 30.0 POMC PDYN OPRM1 CRH CNR1
16 heroin dependence 29.8 PDYN OPRM1 OPRD1 DRD2 ANKK1
17 anxiety 29.8 SLC6A4 OPRL1 CRH CNR1
18 post-traumatic stress disorder 29.8 SLC6A4 DRD2 CRH CNR1
19 migraine without aura 29.8 SLC6A4 DRD3 DRD2
20 anorexia nervosa 29.6 SLC6A4 POMC CRH
21 migraine with or without aura 1 29.6 SLC6A4 DRD3 DRD2 CNR1
22 phobic disorder 29.6 SLC6A4 OPRK1
23 mood disorder 29.5 SLC6A4 POMC DRD3 DRD2 CRH
24 cannabis abuse 29.5 CNR1 CHRNB3
25 psychotic disorder 29.4 SLC6A4 DRD3 DRD2 DRD1
26 tobacco addiction 29.1 SLC6A4 OPRM1 DRD2 CHRNB3 CHRNA6 ANKK1
27 attention deficit-hyperactivity disorder 29.1 SLC6A4 OPRM1 DRD3 DRD2 DRD1 ANKK1
28 eating disorder 29.0 SLC6A4 POMC DRD2 CRH CNR1
29 obsessive-compulsive disorder 28.6 SLC6A4 PDYN DRD3 DRD2 DRD1 CRH
30 pain agnosia 28.5 POMC PNOC PDYN OPRM1 OPRL1 OPRK1
31 disease of mental health 28.3 SLC6A4 POMC PDYN OPRM1 DRD3 DRD2
32 alcohol dependence 26.0 SLC6A4 POMC PNOC PDYN OPRM1 OPRL1
33 cannabis dependence 11.3
34 malaria 11.0
35 barbiturate dependence 11.0
36 alcohol-induced mental disorder 10.6 SLC6A4 DRD2
37 atypical depressive disorder 10.5 SLC6A4 CRH
38 allergic encephalomyelitis 10.5 POMC CRH
39 gangliocytoma 10.5 POMC CRH
40 alexithymia 10.5 SLC6A4 DRD2 ANKK1
41 hypothalamic disease 10.5 POMC CRH
42 cyclic vomiting syndrome 10.4 OPRM1 CNR1
43 retrograde amnesia 10.4 SLC6A4 POMC PDYN
44 pituitary carcinoma 10.4 POMC CRH
45 delusional disorder 10.4 DRD3 DRD2
46 early-onset schizophrenia 10.4 DRD2 DRD1
47 acth deficiency, isolated 10.3 POMC CRH
48 hypoadrenalism 10.3 POMC CRH
49 chronic fatigue syndrome 10.3 SLC6A4 POMC CRH
50 impulse control disorder 10.3 DRD3 DRD2 ANKK1

Graphical network of the top 20 diseases related to Drug Dependence:



Diseases related to Drug Dependence

Symptoms & Phenotypes for Drug Dependence

MGI Mouse Phenotypes related to Drug Dependence:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.34 CHRM2 CHRNB3 CNR1 CRH DRD1 DRD2
2 homeostasis/metabolism MP:0005376 10.2 ACKR1 CHRM2 CNR1 CRH DRD1 DRD2
3 growth/size/body region MP:0005378 10.11 CHRM2 CNR1 CRH DRD1 DRD2 DRD3
4 integument MP:0010771 10.1 CHRM2 CNR1 CRH DRD1 DRD2 OPRD1
5 adipose tissue MP:0005375 10.06 CNR1 CRH DRD1 DRD2 DRD3 OPRM1
6 nervous system MP:0003631 10 CHRM2 CHRNA6 CNR1 CRH DRD1 DRD2
7 digestive/alimentary MP:0005381 9.95 CNR1 DRD1 DRD2 DRD3 OPRK1 OPRM1
8 no phenotypic analysis MP:0003012 9.56 CNR1 CRH DRD2 OPRD1 OPRM1 PDYN
9 normal MP:0002873 9.23 CNR1 CRH DRD1 DRD2 OPRL1 OPRM1

Drugs & Therapeutics for Drug Dependence

Drugs for Drug Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
2
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Methadone Approved, Illicit Phase 4 76-99-3 4095
5
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
6 Serotonin Receptor Agonists Phase 4
7 Serotonin Antagonists Phase 4
8 Serotonin Agents Phase 4
9 Serotonin 5-HT2 Receptor Antagonists Phase 4
10 Antidepressive Agents Phase 4
11 Serotonin 5-HT1 Receptor Agonists Phase 4
12 Dopamine D2 Receptor Antagonists Phase 4
13 Excitatory Amino Acid Antagonists Phase 4
14 Excitatory Amino Acids Phase 4
15 Anesthetics, General Phase 4
16 Anesthetics, Dissociative Phase 4
17 Anesthetics, Intravenous Phase 4
18 Anti-Arrhythmia Agents Phase 4
19 Sodium Channel Blockers Phase 4
20 Diuretics, Potassium Sparing Phase 4
21 Anti-Inflammatory Agents Phase 4
22 Oxytocics Phase 4
23 Opiate Alkaloids Phase 4
24
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
25
Biperiden Approved, Investigational Phase 3 514-65-8 2381
26
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
27
Gabapentin Approved, Investigational Phase 2, Phase 3 60142-96-3 3446
28
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
29
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
30
Ondansetron Approved Phase 2, Phase 3 99614-02-5 4595
31
Sevoflurane Approved, Vet_approved Phase 2, Phase 3 28523-86-6 5206
32
Propofol Approved, Investigational, Vet_approved Phase 2, Phase 3 2078-54-8 4943
33
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
34
Ketorolac Approved Phase 2, Phase 3 74103-06-3, 66635-83-4 3826
35
Succinylcholine Approved Phase 2, Phase 3 306-40-1 5314
36
Rocuronium Approved Phase 2, Phase 3 119302-91-9, 143558-00-3 441290
37
Clonidine Approved Phase 2, Phase 3 4205-90-7 2803
38
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
39
Heroin Phase 3 5462328
40 Parasympatholytics Phase 3
41 Muscarinic Antagonists Phase 3
42 Antiparkinson Agents Phase 3
43 Cholinergic Antagonists Phase 3
44 Biperiden lactate Phase 3
45 Neurotransmitter Agents Phase 2, Phase 3
46 Autonomic Agents Phase 2, Phase 3
47 Psychotropic Drugs Phase 2, Phase 3
48 Anticonvulsants Phase 2, Phase 3
49 Adrenergic Agents Phase 2, Phase 3
50 Adrenergic Agonists Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 137)
# Name Status NCT ID Phase Drugs
1 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
2 Project STRIDE2 - Seek/Test/Retain: PLWHA and Opioid Users in Washington, DC Completed NCT03583138 Phase 4 buprenorphine
3 Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth Completed NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
4 Intensive Outpatient v. Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
5 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
6 Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
7 On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings Completed NCT00317460 Phase 4
8 Intravenous Lidocaine for Perioperative and Postoperative Analgesia Recruiting NCT03921567 Phase 4 Lidocaine Hydrochloride;Lidocaine Hydrochloride and Ketamine;Placebo
9 Neuroplasticity Following Theta-Burst Stimulation in Cocaine Use Recruiting NCT02927236 Phase 4
10 Oxytocin and Cognitive Behavioral Therapy in Drug Dependence Terminated NCT00975416 Phase 4 Intranasal Oxytocin;Placebo
11 A Randomized Controlled Trial Testing Buprenorphine as a Treatment in Opiate Dependent Pain Patients Terminated NCT00552578 Phase 4 buprenorphine/naloxone;buprenorphine/naloxone
12 A Randomized Controlled Trial Comparing Buprenorphine/Naloxone With Naltrexone for Treatment in Opioid Dependent Adolescents and Young Adults Withdrawn NCT01015066 Phase 4 Buprenorphine/naloxone;Naltrexone
13 Job Seekers Training for Patients With Drug Dependence Completed NCT00102362 Phase 3
14 Cocaine/Crack Dependence: A Study of the Possible Reduction of Compulsion Under the Use of Biperiden Completed NCT01251393 Phase 3 Biperiden;Placebo
15 Linkage of Alcohol Abusers to Primary Care Completed NCT00278447 Phase 3
16 BOSCOT: A Randomised Control Trial of Cognitive Behavioural Therapy Plus Treatment as Usual Versus Treatment as Usual in the Treatment of Borderline Personality Disorder Completed NCT00538135 Phase 3
17 Preventing Drug Use in Low Income Clinic Populations Completed NCT01942876 Phase 2, Phase 3
18 Reinforcing Effects of Intravenous Buprenorphine Versus Buprenorphine/Naloxone in Buprenorphine-maintained Intravenous Drug Users (P05207) Completed NCT00710385 Phase 3 Heroin;Naloxone;Low Bup Dose;High Bup Dose;Low Bup/Nal Dose;High Bup/Nal Dose;Placebo (PCB)
19 The Impact of Concomitant Ultra Low Dose Infusion Naloxone and Therapeutic Infusion Opioid on Opioid Requirements in Pediatric ICU Patients Completed NCT00286052 Phase 3 Low Dose Naloxone
20 Child and Adolescent Trial for Cardiovascular Health (CATCH) Completed NCT00000467 Phase 3
21 Effect of Intraoperative and Post-operative Opioids on Persistent Opioid Use in the Surgical Patient Recruiting NCT03367988 Phase 2, Phase 3 Opioid Anesthesia;Opioid-free Anesthesia
22 Improving Treatment Outcomes for Prescription Opioid Dependence Recruiting NCT02543944 Phase 2, Phase 3 Gabapentin;Buprenorphine;Clonidine;Naltrexone (oral);Naltrexone (depot);Placebo
23 Effectiveness of Extended Treatment for Drug Dependence - City Supplement Completed NCT01153464 Phase 2
24 Efficacy of Drug-HIV Counseling Among IDU at Methadone Clinics in Jakarta Completed NCT01360463 Phase 2
25 Efficacy of Varenicline for Smokeless Tobacco Use in India Completed NCT01098305 Phase 2 Varenicline
26 Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study Completed NCT00611130 Phase 2 vigabatrin;placebo
27 Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence Completed NCT02437344 Phase 2 CI-581aa;Naltrexone titration and XR-NTX initiation
28 A Single-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Analgesic Efficacy and Safety of CR845 Dosed in Patients With Pain Following Bunionectomy Surgery Completed NCT01789476 Phase 2 CR845;Placebo
29 A Double-Blind, Randomized, Placebo and Active-Controlled, Six-Period Crossover Study to Evaluate the Likeability, Safety, and Abuse Liability of NRP104 in Healthy Adult Volunteers With Histories of Stimulant Abuse Completed NCT00248092 Phase 1, Phase 2 NRP104
30 A Double-Blind Placebo- and Active-Controlled, Single-Dose Crossover PD and PK Study to Evaluate the Safety, Tolerability and Abuse Liability of IV Administered NRP104 25 mg and 50 mg in Adult Volunteers With Histories of Stimulant Abuse Completed NCT00247572 Phase 2 NRP104
31 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Analgesic Efficacy and Safety of Intravenous CR845 During the Post-Operative Period in Subjects Undergoing Laparoscopic-Assisted Hysterectomy Completed NCT00877799 Phase 2 CR845;CR845;CR845;Placebo;Placebo
32 Group IPT for Women Prisoners With Comorbid Substance Use and Depression Completed NCT00606996 Phase 2
33 A Multi-Center, Double-Randomized, Double Blind, Placebo Controlled Study to Evaluate the Analgesic Efficacy and Safety of Intravenous CR845 Dosed Preoperatively and Postoperatively in Patients Undergoing a Laparoscopic Hysterectomy Completed NCT01361568 Phase 2 CR845;Placebo;CR845;Placebo
34 Brief Intervention for Regular Prescription Drug Use and Prescription Drug Use Disorders in General Hospital Completed NCT00514839 Phase 2
35 Nicotine Delivery and Subjective Effects of 4 mg Nicotine Polacrilex Chewing Gum Compared With Swedish Portion Snus Completed NCT01182129 Phase 1, Phase 2 Nicotine;Nicotine
36 Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse Completed NCT01137890 Phase 1, Phase 2 Zonisamide;Placebo;Cocaine Hydrochloride
37 Clinical Trial of Topiramate for Cocaine Addiction Completed NCT00685178 Phase 2 topiramate;placebo + NonCR
38 An Open Label, Flexible Dose Study of Very Low Doses of Naltrexone-Buprenorphine Transfer to Extend-Release Naltrexone (VIVITROL®) in Opioid Addiction Completed NCT01690546 Phase 2 very low dose naltrexone;extended release naltrexone;buprenorphine/naloxone
39 Screening Medications for Cocaine Cessation and Relapse Prevention Completed NCT00218023 Phase 2 Modafinil;Levodopa/Carbidopa;Naltrexone HCl;Placebo
40 Buprenorphine Effectiveness Evaluation in HIV Enhancement (BEEHIVE): A Randomized Trial of HIV Clinic-based Buprenorphine/Naloxone vs. Case Management and Referral in Opioid-dependent Individuals Completed NCT00130819 Phase 2
41 Brief Introductory Therapy for Opioid Dependence Completed NCT00406484 Phase 2
42 Medications Development for Alcohol Abuse: NMDA Agents -- A Placebo-Controlled Trial of Memantine for Alcohol Dependence Completed NCT00246415 Phase 2 Memantine
43 Youth Drug Abuse Family and Cognitive-Behavioral Therapy Completed NCT00198874 Phase 2
44 A Double-Blind,Randomized,Placebo-Controlled Trial of Mecamylamine Hydrochloride for the Treatment of SSRI-Refractory Major Depressive Disorder. Completed NCT00319319 Phase 2 Mecamylamine hydrochloride (Inversine)
45 Aminophylline Improves Early Postoperative Cognitive Recovery After Sevoflurane Anaesthesia: A Dose-Dependent Study Completed NCT01022151 Phase 2 Placebo [group P];0.2 mL/kg of aminophylline 10 mg/mL [group A2];0.2 mL/kg of aminophylline 15 mg/mL [group A3];0.2 mL/kg of aminophylline 20 mg/mL [group A4];0.2 mL/kg of aminophylline 25 mg/mL [group A5];Doxapram 1 mg/kg [group D]
46 Psilocybin-facilitated Treatment for Cocaine Use: A Pilot Study Recruiting NCT02037126 Phase 2 Psilocybin;Diphenhydramine
47 Efficacy and Safety Study of a IMSS Developed Phytopharmaceutical for the Treatment of Anxiety. Double Blind and Randomized Clinical Trial Controlled With Alprazolam Recruiting NCT03702803 Phase 2 alprazolam 1mg
48 Frontoparietal Synchronization to Modulate Drug Craving in Opioid Use Disorder: A Randomized Experimental Trial Recruiting NCT03907644 Phase 1, Phase 2
49 Preliminar Efficacy and Safety of Ibogaine in the Treatment of Methadone Not yet recruiting NCT04003948 Phase 2 Ibogaine Hydrochloride
50 Placebo-Controlled Evaluation of the Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use Terminated NCT00430573 Phase 2 D-cycloserine;Placebo

Search NIH Clinical Center for Drug Dependence

Genetic Tests for Drug Dependence

Anatomical Context for Drug Dependence

MalaCards organs/tissues related to Drug Dependence:

41
Testes, Brain, Cortex, Prefrontal Cortex, Liver, Heart, Amygdala

Publications for Drug Dependence

Articles related to Drug Dependence:

(show top 50) (show all 3711)
# Title Authors PMID Year
1
Association of a variant in the muscarinic acetylcholine receptor 2 gene (CHRM2) with nicotine addiction. 9 38
19644963 2010
2
The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonists. 9 38
19359525 2009
3
Peptide kappa opioid receptor ligands: potential for drug development. 9 38
19430912 2009
4
Interaction between two independent CNR1 variants increases risk for cocaine dependence in European Americans: a replication study in family-based sample and population-based sample. 9 38
19052543 2009
5
Haplotypic variants in DRD2, ANKK1, TTC12, and NCAM1 are associated with comorbid alcohol and drug dependence. 9 38
18828801 2008
6
A role for brain stress systems in addiction. 9 38
18614026 2008
7
Association analysis of genes encoding the nociceptin receptor (OPRL1) and its endogenous ligand (PNOC) with alcohol or illicit drug dependence. 9 38
17910740 2008
8
The opioid system in alcohol and drug dependence: family-based association study. 9 38
17503481 2007
9
Alcohol dependence with comorbid drug dependence: genetic and phenotypic associations suggest a more severe form of the disorder with stronger genetic contribution to risk. 9 38
17567401 2007
10
Dopamine D3 receptor ligands for the treatment of tobacco dependence. 9 38
17155853 2007
11
11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. 9 38
17015906 2006
12
[How do self-help agencies work for recovery of drug dependence in Japan?]. 9 38
17037343 2006
13
Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. 9 38
16476706 2006
14
The dopamine D3 receptor and drug dependence: effects on reward or beyond? 9 38
15963538 2005
15
Allelic association of a dopamine transporter gene polymorphism with antisocial behaviour in heroin-dependent patients. 9 38
16109590 2005
16
CHRM2 gene predisposes to alcohol dependence, drug dependence and affective disorders: results from an extended case-control structured association study. 9 38
16000316 2005
17
How individual sensitivity to opiates can be predicted by gene analyses. 9 38
15925706 2005
18
Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence. 9 38
15542743 2004
19
Analysis of monoamine oxidase A (MAO-A) promoter polymorphism in male heroin-dependent subjects: behavioural and personality correlates. 9 38
15088154 2004
20
[A study on effectiveness of recovery from drug dependence by participates with "DARC"]. 9 38
15160890 2004
21
Temporal upregulation of prodynorphin mRNA in the primate striatum after cocaine self-administration. 9 38
12786988 2003
22
Association study of cannabinoid receptor gene (CNR1) alleles and drug dependence. 9 38
11526463 2001
23
Family-based study of DRD2 alleles in alcohol and drug dependence. 9 38
11054774 2000
24
[A study of recovery factor about drug addiction recovery center "DARC"]. 9 38
11019561 2000
25
Association of alcohol or other drug dependence with alleles of the mu opioid receptor gene (OPRM1). 9 38
9756053 1998
26
Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? 9 38
9693390 1998
27
Homozygosity at the dopamine D3 receptor gene is associated with opiate dependence. 9 38
9702742 1998
28
Enhanced stimulatory adenylyl cyclase signaling during opioid dependence is associated with a reduction in palmitoylated Gs alpha. 9 38
9415709 1997
29
Mu opioid receptor gene variants: lack of association with alcohol dependence. 9 38
9399694 1997
30
The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. 9 38
8845863 1996
31
Association and linkage studies of the TAQI A1 allele at the dopamine D2 receptor gene in samples of female and male alcoholics. 9 38
7485259 1995
32
Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis. 38
30968175 2019
33
Chasing the rainbow: pleasure, sex-based sociality and consumerism in navigating and exiting the Irish Chemsex scene. 38
30600787 2019
34
Affective startle modulation and psychopathology: Implications for appetitive and defensive brain systems. 38
31129237 2019
35
Zolpidem stimulant effect: Induced mania case report and systematic review of cases. 38
31071363 2019
36
Triple arginines as molecular determinants for pentameric assembly of the intracellular domain of 5-HT3A receptors. 38
31409663 2019
37
D1- and D2-like receptors in the dentate gyrus region of the hippocampus are involved in the reinstatement induced by a subthreshold dose of morphine and forced swim stress in extinguished morphine-CPP in rats. 38
31414832 2019
38
The Inhibition of RasGRF2, But Not RasGRF1, Alters Cocaine Reward in Mice. 38
31182637 2019
39
Cognitive interference as a possible therapeutic strategy to prevent expression of benzodiazepine withdrawal. 38
31299121 2019
40
Molecular Mechanisms Associated with Nicotine Pharmacology and Dependence. 38
31267166 2019
41
Familial factors and the risk of borderline personality pathology: genetic and environmental transmission. 38
31317840 2019
42
Genome-wide association study identifies loci associated with liability to alcohol and drug dependence that is associated with variability in reward-related ventral striatum activity in African- and European-Americans. 38
31099175 2019
43
[Impact on success rates among drugdependent men and women treated in separate therapeutic groups.] 38
31313757 2019
44
Effects of repetitive transcranial magnetic stimulation (rTMS) on craving and substance consumption in patients with substance dependence: a systematic review and meta-analysis. 38
31328353 2019
45
Access to means of lethal overdose among psychiatric patients with co-morbid physical health problems: Analysis of national suicide case series data from the United Kingdom. 38
31301620 2019
46
Inhibition of alpha7 nicotinic receptors in the ventral hippocampus selectively attenuates reinstatement of morphine-conditioned place preference and associated changes in AMPA receptor binding. 38
29667304 2019
47
Modeling the Prescription Opioid Epidemic. 38
31012032 2019
48
Corticostriatal plasticity in the nucleus accumbens core. 38
31298422 2019
49
Limonene Inhibits Methamphetamine-Induced Sensitizations via the Regulation of Dopamine Receptor Supersensitivity. 38
30739426 2019
50
Methamphetamine (MA) Use Induces Specific Changes in LINE-1 Partial Methylation Patterns, Which Are Associated with MA-Induced Paranoia: a Multivariate and Neuronal Network Study. 38
30302724 2019

Variations for Drug Dependence

Expression for Drug Dependence

Search GEO for disease gene expression data for Drug Dependence.

Pathways for Drug Dependence

Pathways related to Drug Dependence according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 POMC PNOC PENK PDYN OPRM1 OPRL1
2
Show member pathways
12.83 POMC PNOC PENK PDYN OPRM1 OPRL1
3
Show member pathways
12.75 OPRM1 DRD3 DRD2 DRD1 CHRNA6 CHRM2
5
Show member pathways
11.74 PDYN DRD2 DRD1
6 11.71 POMC OPRM1 OPRD1
7
Show member pathways
11.71 DRD3 DRD2 DRD1 CHRM2
8
Show member pathways
11.64 DRD3 DRD2 CHRNA6
9 11.63 DRD3 CNR1 CHRM2 ACKR1
10 10.78 DRD3 DRD2 DRD1
11 10.28 POMC CRH

GO Terms for Drug Dependence

Cellular components related to Drug Dependence according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.95 PNOC PENK PDYN OPRK1 CRH CHRM2
2 dendrite GO:0030425 9.95 PNOC PENK PDYN OPRM1 OPRK1 DRD2
3 glutamatergic synapse GO:0098978 9.92 DRD3 DRD2 DRD1 CNR1 CHRM2
4 postsynaptic membrane GO:0045211 9.86 OPRD1 CHRNB3 CHRNA6 CHRM2
5 membrane raft GO:0045121 9.85 SLC6A4 OPRM1 OPRD1 CNR1
6 perikaryon GO:0043204 9.83 PENK OPRM1 OPRK1 DRD2 CRH
7 GABA-ergic synapse GO:0098982 9.76 DRD3 DRD2 DRD1 CNR1
8 axon terminus GO:0043679 9.7 PNOC PENK PDYN OPRK1 OPRD1 DRD2
9 dopaminergic synapse GO:0098691 9.62 DRD3 DRD2 CHRNB3 CHRNA6
10 acetylcholine-gated channel complex GO:0005892 9.57 CHRNB3 CHRNA6
11 symmetric synapse GO:0032280 9.51 PENK CHRM2
12 integral component of postsynaptic membrane GO:0099055 9.5 SLC6A4 OPRM1 OPRK1 DRD2 DRD1 CHRNA6
13 spine apparatus GO:0097444 9.49 OPRM1 OPRD1
14 integral component of presynaptic membrane GO:0099056 9.28 SLC6A4 OPRM1 OPRK1 OPRD1 DRD2 DRD1
15 integral component of membrane GO:0016021 10.35 SLC6A4 OPRM1 OPRL1 OPRK1 OPRD1 DRD3
16 plasma membrane GO:0005886 10.27 SLC6A4 PNOC PENK PDYN OPRM1 OPRL1
17 integral component of plasma membrane GO:0005887 10.03 SLC6A4 OPRM1 OPRL1 OPRK1 OPRD1 DRD3

Biological processes related to Drug Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.95 OPRM1 OPRD1 DRD1 CNR1 CHRM2
2 excitatory postsynaptic potential GO:0060079 9.93 OPRM1 DRD2 CHRNB3 CHRNA6
3 locomotory behavior GO:0007626 9.93 PENK OPRM1 OPRK1 DRD3 DRD2 DRD1
4 sensory perception of pain GO:0019233 9.92 PENK OPRM1 OPRL1 OPRK1 CNR1
5 response to estradiol GO:0032355 9.91 SLC6A4 PENK OPRL1
6 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.91 OPRM1 OPRL1 OPRK1 OPRD1
7 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.91 DRD3 DRD2 CNR1 CHRM2
8 regulation of synaptic vesicle exocytosis GO:2000300 9.91 DRD2 DRD1 CHRNB3 CHRNA6 CHRM2
9 response to ethanol GO:0045471 9.91 PENK OPRM1 OPRK1 DRD3 DRD2 CRH
10 response to toxic substance GO:0009636 9.9 SLC6A4 PENK DRD2
11 memory GO:0007613 9.89 SLC6A4 DRD1 CNR1
12 regulation of sensory perception of pain GO:0051930 9.89 OPRM1 OPRL1 OPRK1 OPRD1
13 response to nicotine GO:0035094 9.89 PENK DRD2 CNR1 CHRNB3 CHRNA6
14 negative regulation of blood pressure GO:0045776 9.88 OPRL1 DRD3 DRD2 CNR1
15 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.87 OPRM1 OPRK1 OPRD1
16 learning or memory GO:0007611 9.87 DRD3 CRH CNR1
17 eating behavior GO:0042755 9.87 OPRM1 OPRL1 OPRK1 OPRD1
18 visual learning GO:0008542 9.86 DRD3 DRD2 DRD1
19 behavioral response to cocaine GO:0048148 9.86 OPRK1 DRD3 DRD2 DRD1
20 neuropeptide signaling pathway GO:0007218 9.86 POMC PNOC PENK PDYN OPRM1 OPRL1
21 signal transduction GO:0007165 9.86 POMC PNOC PENK OPRM1 OPRL1 OPRK1
22 response to radiation GO:0009314 9.85 PENK OPRM1 OPRK1
23 synaptic transmission, dopaminergic GO:0001963 9.84 DRD3 DRD2 DRD1 CRH
24 response to amphetamine GO:0001975 9.83 DRD3 DRD2 DRD1
25 associative learning GO:0008306 9.82 DRD2 DRD1 CRH
26 dopamine receptor signaling pathway GO:0007212 9.81 DRD3 DRD2 DRD1
27 estrous cycle GO:0044849 9.81 OPRM1 OPRL1 OPRK1
28 prepulse inhibition GO:0060134 9.8 DRD3 DRD2 DRD1
29 response to morphine GO:0043278 9.8 PENK OPRM1 OPRK1 DRD3 DRD2 CNR1
30 dopamine metabolic process GO:0042417 9.79 DRD3 DRD2 DRD1
31 sensory perception GO:0007600 9.78 PNOC OPRM1 OPRL1 OPRK1
32 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.77 OPRM1 DRD3 DRD1
33 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.76 DRD3 DRD2 DRD1
34 temperature homeostasis GO:0001659 9.74 DRD2 DRD1
35 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.74 DRD3 DRD2
36 regulation of NMDA receptor activity GO:2000310 9.74 OPRM1 CRH
37 negative regulation of protein secretion GO:0050709 9.73 DRD3 DRD2
38 startle response GO:0001964 9.73 PENK DRD2
39 striatum development GO:0021756 9.73 DRD2 DRD1
40 regulation of synaptic transmission, GABAergic GO:0032228 9.73 DRD2 CNR1
41 opioid receptor signaling pathway GO:0038003 9.73 OPRM1 OPRL1 OPRK1 OPRD1
42 positive regulation of urine volume GO:0035810 9.72 OPRL1 DRD2
43 positive regulation of renal sodium excretion GO:0035815 9.72 DRD3 DRD2
44 locomotory exploration behavior GO:0035641 9.72 PENK CRH
45 grooming behavior GO:0007625 9.72 DRD2 DRD1
46 maternal behavior GO:0042711 9.72 OPRK1 DRD1
47 G protein-coupled receptor internalization GO:0002031 9.71 DRD3 DRD2
48 peristalsis GO:0030432 9.71 DRD2 DRD1
49 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.71 DRD3 DRD2
50 negative regulation of voltage-gated calcium channel activity GO:1901386 9.71 OPRL1 DRD2

Molecular functions related to Drug Dependence according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.61 PNOC PENK CRH
2 drug binding GO:0008144 9.58 DRD3 DRD2 CNR1
3 G-protein alpha-subunit binding GO:0001965 9.55 OPRM1 DRD1
4 adrenergic receptor activity GO:0004935 9.54 DRD3 DRD2
5 dopamine binding GO:0035240 9.54 DRD3 DRD2 DRD1
6 acetylcholine-gated cation-selective channel activity GO:0022848 9.52 CHRNB3 CHRNA6
7 acetylcholine binding GO:0042166 9.51 CHRNB3 CHRNA6
8 dopamine neurotransmitter receptor activity GO:0004952 9.5 DRD3 DRD2 DRD1
9 acetylcholine receptor activity GO:0015464 9.49 CHRNB3 CHRNA6
10 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.48 DRD3 DRD2
11 receptor serine/threonine kinase binding GO:0033612 9.46 OPRK1 OPRD1
12 neuropeptide binding GO:0042923 9.46 OPRM1 OPRL1 OPRK1 OPRD1
13 opioid peptide activity GO:0001515 9.43 PNOC PENK PDYN
14 G protein-coupled receptor activity GO:0004930 9.32 OPRM1 OPRL1 OPRK1 OPRD1 DRD3 DRD2
15 opioid receptor activity GO:0004985 9.26 OPRM1 OPRL1 OPRK1 OPRD1

Sources for Drug Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....